Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

DM73 May. 13 at 11:23 PM

$SRPT GL everyone I am officially done with this stock n board. There are greater opportunities out there. Best to all!

1 · Reply

Initiator1 May. 13 at 11:16 PM

$SRPT I wonder what ‘crafty logic’ would the longs come up with now. it’s a useless piece of junk. PMOs are snake oil. Elevidys works but the confidence is lost forever. Management is inept and arrogant

0 · Reply

biomaster22 May. 13 at 11:13 PM

$SRPT when is Doug leaving we need another voice WS hates him!

0 · Reply

Czar_of_Losses May. 13 at 7:49 PM

$SRPT I also do not understand why they are not buying back shares. It's so ridiculous to me that the stock has been stuck in the 15-25$ corridor for over a year and management are patting themselves on the back giving themselves compensation packages while holders sit being able to do nothing. We don't get dividends aaaa Doug you dog

3 · Reply

Czar_of_Losses May. 13 at 7:33 PM

$SRPT Why can Doug not just sell. It's so irritating. They lost the patent infringement lawsuit, idk how they will resolve this while they have debts out the wazzooh. Please Doug please just sell

0 · Reply

maxmemax May. 13 at 7:08 PM

$SRPT bagholders, are you worried about RGX202 yet? Don't worry, the worst that can happen is 400M$ / year less revenue plus some inventory write-off. Hopefully Doug learned his lesson to not overestimate demand and won't lose half a billion $ to Catalent yet again

1 · Reply

Gladiator007 May. 13 at 6:53 PM

$SRPT Pumping AI stocks and shorting most of the other company stocks. Never saw this much manipulation before.

1 · Reply

kitty_3 May. 13 at 6:33 PM

$SRPT I dont think much will happen until RGNX releases their data. Need to do some research but not sure when that is.

1 · Reply

Find_the_Cure May. 13 at 6:27 PM

$SRPT they don’t want to let this run…. Too many shorts will be burned to a crisp unless they’re hedged.

0 · Reply

george4it May. 13 at 4:57 PM

$SRPT Bought another 1000 at 18.78. No way this, at a minimum, doesn’t get back low 20s soon.

2 · Reply

Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year

May 6, 2026, 4:30 PM EDT - 7 days ago

Sarepta Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:05 PM EDT - 7 days ago

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

Apr 22, 2026, 8:30 AM EDT - 21 days ago

Sarepta Therapeutics to Announce First Quarter 2026 Financial Results

2026-04-16T16:20:19.000Z - 27 days ago

Roche decision could hurt Sarepta in U.S., says H.C. Wainwright

2026-04-07T15:08:48.000Z - 5 weeks ago

Sarepta price target raised to $19 from $18 at RBC Capital

Mar 31, 2026, 4:05 PM EDT - 6 weeks ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-03-26T12:40:44.000Z - 6 weeks ago

Deutsche ups Sarepta target, says 35% stock rally overdone

2026-03-26T12:37:02.000Z - 6 weeks ago

Sarepta price target raised to $35 from $29 at Wedbush

2026-03-26T09:56:24.000Z - 6 weeks ago

Sarepta price target raised to $13 from $9 at Citi

2026-03-25T19:50:31.000Z - 7 weeks ago

Sarepta price target raised to $25 from $20 at Morgan Stanley

2026-03-25T14:10:14.000Z - 7 weeks ago

Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink

2026-03-25T13:55:34.000Z - 7 weeks ago

Sarepta early DM1 data ‘appear promising,’ says Oppenheimer

Mar 25, 2026, 8:30 AM EDT - 7 weeks ago

Sarepta Therapeutics Transcript: Study result

2026-03-25T12:10:47.000Z - 7 weeks ago

Sarepta announces first clinical data from pipeline targeting FSHD1, DM1

Mar 25, 2026, 8:05 AM EDT - 7 weeks ago

Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

Mar 24, 2026, 4:05 PM EDT - 7 weeks ago

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

2026-03-19T14:45:29.000Z - 7 weeks ago

Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer

2026-03-19T12:46:48.000Z - 7 weeks ago

Sarepta provides regulatory update on Amondys 45, Vyondys 53

Mar 19, 2026, 8:30 AM EDT - 7 weeks ago

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

Mar 16, 2026, 8:33 AM EDT - 2 months ago

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Mar 3, 2026, 1:50 PM EST - 2 months ago

Sarepta Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 27, 2026, 9:00 AM EST - 2 months ago

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Feb 26, 2026, 8:30 AM EST - 2 months ago

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Feb 26, 2026, 5:05 AM EST - 2 months ago

Sarepta Therapeutics CEO Ingram to retire by year end

Feb 25, 2026, 4:30 PM EST - 2 months ago

Sarepta Therapeutics Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:05 PM EST - 2 months ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Feb 24, 2026, 9:07 AM EST - 2 months ago

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 24, 2026, 8:30 AM EST - 2 months ago

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 8:30 AM EST - 3 months ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 8:30 AM EST - 3 months ago

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Jan 26, 2026, 8:53 AM EST - 3 months ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:30 AM EST - 3 months ago

Sarepta Therapeutics Transcript: Study result

Jan 26, 2026, 8:10 AM EST - 3 months ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:00 AM EST - 3 months ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 23, 2026, 4:05 PM EST - 3 months ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 12, 2026, 12:00 PM EST - 4 months ago

Sarepta Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 11:58 AM EST - 4 months ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 9:30 AM EST - 4 months ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 7, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 5, 2026, 8:30 AM EST - 4 months ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 7:00 AM EST - 5 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Nov 25, 2025, 8:57 AM EST - 6 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 24, 2025, 7:30 AM EST - 6 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Nov 24, 2025, 7:30 AM EST - 6 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 14, 2025, 2:54 PM EST - 6 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:08 PM EST - 6 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 4, 2025, 9:55 AM EST - 6 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 6:20 AM EST - 6 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 4:27 AM EST - 6 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 3, 2025, 6:26 PM EST - 6 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 4:30 PM EST - 6 months ago

Sarepta Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:24 PM EST - 6 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:05 PM EST - 6 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Oct 27, 2025, 4:05 PM EDT - 7 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 23, 2025, 6:46 AM EDT - 7 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Oct 3, 2025, 8:30 AM EDT - 7 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress

Sep 5, 2025, 9:00 AM EDT - 8 months ago

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Aug 25, 2025, 3:11 AM EDT - 9 months ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 23, 2025, 7:08 AM EDT - 9 months ago

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 21, 2025, 7:00 AM EDT - 9 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

DM73 May. 13 at 11:23 PM

$SRPT GL everyone I am officially done with this stock n board. There are greater opportunities out there. Best to all!

1 · Reply

Initiator1 May. 13 at 11:16 PM

0 · Reply

biomaster22 May. 13 at 11:13 PM

$SRPT when is Doug leaving we need another voice WS hates him!

0 · Reply

Czar_of_Losses May. 13 at 7:49 PM

3 · Reply

Czar_of_Losses May. 13 at 7:33 PM

$SRPT Why can Doug not just sell. It's so irritating. They lost the patent infringement lawsuit, idk how they will resolve this while they have debts out the wazzooh. Please Doug please just sell

0 · Reply

maxmemax May. 13 at 7:08 PM

1 · Reply

Gladiator007 May. 13 at 6:53 PM

$SRPT Pumping AI stocks and shorting most of the other company stocks. Never saw this much manipulation before.

1 · Reply

kitty_3 May. 13 at 6:33 PM

$SRPT I dont think much will happen until RGNX releases their data. Need to do some research but not sure when that is.

1 · Reply

Find_the_Cure May. 13 at 6:27 PM

$SRPT they don’t want to let this run…. Too many shorts will be burned to a crisp unless they’re hedged.

0 · Reply

george4it May. 13 at 4:57 PM

$SRPT Bought another 1000 at 18.78. No way this, at a minimum, doesn’t get back low 20s soon.

2 · Reply

Astronaut_Trades May. 13 at 4:32 PM

$SRPT 4 intra day pump n dumps in back to back days someone is acquiring BIG using market prices

2 · Reply

BB_88_ May. 13 at 4:28 PM

$SRPT in 1k shares 18.71

1 · Reply

iCro93 May. 13 at 4:13 PM

$SRPT yes and than what ? buy the next stock at fresh highs, sell again for a loss and go on. Dollar cost average , never try to time the market. Time in the market matters. DCA gl Btw. This isn’t garbage at all, heavily shorted. Positive cash flow, making money ( 99% of bios doesn’t make any money). Huge pipeline, owning a lot of arrows heads pipeline too. Stfu pls :)

1 · Reply

rasp86 May. 13 at 4:04 PM

$SRPT any reasons to hold this garbage ? Im really thinking of talking a lose here...what a waste of time so many opportunities on the market.

1 · Reply

ProspectTrends May. 13 at 3:53 PM

$SRPT ughh terrible trade jumping into this one. Gonna hold these calls a little longer but its not looking good.

1 · Reply

DM73 May. 13 at 3:36 PM

$SRPT shoulda bought $RVI

1 · Reply

Find_the_Cure May. 13 at 3:09 PM

$SRPT bemusing!! It’s really a big joke how this MM is manipulating these shares like a ping pong ball. Asshole!!

0 · Reply

Astrid00 May. 13 at 3:00 PM

$SRPT games

0 · Reply

DM73 May. 13 at 3:00 PM

$SRPT this is psychologically destroying retail investors

1 · Reply

Find_the_Cure May. 13 at 2:43 PM

$SRPT squeeeeeeze that short!!

0 · Reply

Find_the_Cure May. 13 at 2:42 PM

$SRPT we’re going to party like it’s $19.29!!

0 · Reply

Market Cap	2.05B
Revenue (ttm)	2.20B
Net Income (ttm)	-713.41M
EPS (ttm)	N/A
PE Ratio	31.18
Forward PE	6.89
Profit Margin	-32.45%
Debt to Equity Ratio	0.56

Volume	3,413,700
Avg Vol	3,039,206
Day's Range	N/A - N/A
Shares Out	105.58M
Stochastic %K	6%
Beta	0.26
Analysts	Sell
Price Target	$21.78